Navigation Links
Profil Institute Reports Record Growth in Number of Clinical Trials in the Pipeline
Date:5/3/2012

SAN DIEGO, May 3, 2012 /PRNewswire/ -- Profil® Institute for Clinical Research, Inc., a company focused on early phase clinical trials for diabetes and obesity, announced today record growth in the number of clinical trials in the pipeline.  Profil Institute also reports an increase in the number of mid-size biotech and off-shore clients, while maintaining active collaborations with the largest global pharmaceutical companies, driven by a strong demand for Phase I and metabolic disease specialization. 

Profil Institute's advances in early phase drug research and its specific focus on diabetes, obesity and cardiometabolic diseases as it relates to the diabetic patient population have led Profil Institute to be recognized in the pharmaceutical community as the most highly regarded clinical research institute for early phase diabetes drug trials. 

"Pharmaceutical clients are facing increased pressure to be more selective and efficient with their drug candidate trials and as such are turning to specialized institutes like Profil Institute to run more complex and meaningful studies," said Profil Institute CEO Dr. Marcus Hompesch.  "While other CROs are responding to this trend, specialization has been Profil Institute's strategy since the company's inception and our business has grown as a result.  We now have a record number of projects in our pipeline, active collaborations with the largest global pharmaceutical companies, and a rapidly growing number of mid-size pharmaceutical and biotech clients."

Although considered a CRO (Clinical Research Organization), the founders of Profil Institute have never considered their company to accurately fit that description.  Instead they coined the term CRI, Clinical Research Institute, and define it as"uniting independent academic science with the professionalism of the pharmaceutical industry" – combining distinct academic intellect with the means to effectively design and execute clinical trials for their biopharmaceutical clients. In essence, Profil Institute's "deeper value" CRI approach is based on assisting their clients in the design and execution of the most meaningful early phase clinical studies, thereby generating relevant high quality data and accelerating the drug and device development process.

In Profil Institute's case, "specialized," can be added in front of the term CRI because of their disease focus on diabetes, obesity and cardiometabolic diseases.  This concept of a specialized clinical research institute gives Profil Institute a substantial advantage in the industry by enabling Profil Institute to outperform peers in meaningful study design, study execution and study data interpretation.

About Profil® Institute for Clinical Research, Inc.

Profil Institute is world-renowned as a Center of Excellence for diabetes and obesity early phase clinical research.  The company's advances in early phase drug research and its specific focus on diabetes, obesity and cardiometabolic diseases as it relates to the diabetic patient population have led Profil Institute to be the most highly regarded clinical research institute for early phase diabetes drug trials. 

To date, Profil Institute has been involved with every clinically promising drug category and device development in diabetes and in more than 175 clinical studies since the company's inception in 2004. Contributing to Profil Institute's success is that the company is recognized as the leader in automated glucose clamps, considered the "Gold Standard" for the evaluation of anti-diabetic drugs and devices.  The company's key scientists hail from academic centers including the WHO Collaborating Center of Diabetes at the Heinrich-Heine University of Dusseldorf, Columbia University, University of Michigan and Harvard University. For more information visit www.profilinstitute.com.


'/>"/>
SOURCE Profil Institute for Clinical Research, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Profil Institute Continues to Publish New Findings in Metabolic Research
2. Profiler at the cellular level
3. Genesis Biopharma Director William H. Andrews, Ph.D., Profiled in Popular Science Feature Story
4. Halozymes Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
5. Precision Therapeutics Announces New Tumor Profiling Product to Augment Utility of ChemoFx® and Further Personalize Cancer Treatment
6. Cempra Pharmaceuticals Profiles the Broad Spectrum and Potent Activity Profile of Solithromycin (CEM-101) at the 5th Annual PHEMCE Stakeholders Workshop and BARDA Industry Day
7. Reportlinker Adds Merck KGaA: PharmaVitae Profile
8. Reportlinker Adds Cancer Profiling and Pathways: Technologies and Global Markets
9. Reportlinker Adds Shire plc: PharmaVitae Profile
10. Promega Now Offers Complete Solution for Profiling Kinase Inhibitor Compounds Against the Human Kinome
11. DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... CO (PRWEB) , ... April 29, 2016 , ... ... addressing the necessary fundamentals to transform technology into a viable company, CereScan’s CEO, ... growth. Mr. Kelley, a recognized leader and mentor in the Denver area ...
(Date:4/29/2016)... ... ... Intelligent Implant Systems announced today that the two-level components for the Revolution™ Spinal System ... These components expand the capabilities of the system and allow Revolution™ to be utilized ... the company has seen significant sales growth in 1Q 2016, and the system is ...
(Date:4/28/2016)... , April 28, 2016 The ... and Brayton Cryocoolers), Service (Technical Support, Product Repairs & ... - Global Forecast to 2022", published by MarketsandMarkets, the ... Billion by 2022, at a CAGR of 7.29% between ... data Tables and 94 Figures spread through 159 Pages ...
(Date:4/28/2016)... Hill, Conn. (PRWEB) , ... April 28, 2016 ... ... of financing and ongoing support for Connecticut's innovative, growing companies, today announced the ... digital health and financial technology (fintech) companies. , “VentureClash looks to ...
Breaking Biology Technology:
(Date:3/9/2016)... 9, 2016  Crossmatch ® , a leading ... today announced the addition of smart features to ... multi-factor authentication platform. New contextual and application-specific authentication ... security where it,s needed most — while minimizing ... . --> Washington, DC ...
(Date:3/3/2016)...  FlexTech, a SEMI Strategic Association Partner, awarded five ... Development, Leadership in Education, and, in a category new ... year of the FLEXI Awards and the winners ... past years . Judging was done on a ... criteria, by a panel of non-affiliated, independent, industry experts. ...
(Date:3/3/2016)... and DE SOTO, Kansas , ... Stroke Detection Plus® to offer Oncimmune,s Early CDT®-Lung, ... and early detection of lung cancer Early ... unions and individuals. --> Early CDT®-Lung test ... individuals. --> Oncimmune, a leader in early ...
Breaking Biology News(10 mins):